← Ticker index
TAK
Ticker
TAK
Congressional Trades
3
by 1 members
Ticker disclosure brief
Congressional disclosure records for TAK
A ticker-first view of recent disclosures, reported ranges, filing lags, party aggregates, federal awards, lobbying records, and source-linked receipts.
Latest receipt
Virginia Foxx
SELL · 2023-08-29
Largest range
$15K – $50K
Virginia Foxx
Longest observed gap
13d
Virginia Foxx
Highest 30d vs SPY
—
No modeled returns
Purchase rows
2
67%
Sale rows
1
33%
Disclosed midpoint
$73K
range estimate
Unique Traders
1
members
Disclosure timing method
Observed filing gaps are not notice-date findings
The reporting deadline is the earlier of 30 days after notice or 45 days after the transaction. Public disclosure rows provide transaction and filing dates, but do not establish when a member received notice. PoliWealth therefore marks only transaction-to-filing gaps over 45 days as an apparent delay for review; 31–45 day gaps are not labeled late from transaction date alone.
Party Breakdown
Democrats0 · 0%
Republicans3 · 100%
Lobbying filings
all →- 2026-07-10$50KTAKEDA PHARMACEUTICALS AMERICA INC.International tax reform.
- 2026-07-01$40KTAKEDA PHARMACEUTICALS AMERICA INCIssues relating to HR 7299 and other heath issues.
- 2026-06-30$0TAKEDA PHARMACEUTICALS AMERICA INCIssues relating to HR 4299, Protecting Patients' Access to Cancer and Complex Therapies Act, and general healthcare
- 2026-04-20$1.4MTAKEDA PHARMACEUTICALS AMERICA INCFY 2025 Budget Resolution - Pharmaceutical Related Provisions Policies to enhance patient access to medicines in Medicaid including rebate, waiver policy and funding issues Policies to enhance patient access to medicines in Medicare Review of proposed rule regarding testing of Medicare part B prescription drug models Medicare payment proposals Medicare telehealth proposals CMS Transparency in Coverage Final Rule (CMS-9915-F) Request for Regulatory Clarification with Medicare Part B Group (CMS) Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2026 Request for Regulatory Clarification with Medicare Administrative Contractor (CMS) Discussions on biosimilars related to IRA Discussions on spillover related to the IRA Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2027 Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2028 Discussions on reforming the Inflati
- 2026-04-20$50KTAKEDA PHARMACEUTICALS AMERICA INC.Rare Disease Issues. H.R.4299: Protecting Patient Access to Cancer and Complex Therapies Act. General Medicare/Medicaid Issues. Implementation of Inflation Reduction Act of 2022.
- 2026-04-20$30KTAKEDA PHARMACEUTICALS AMERICA INC.General issues related to drug research and innovation.
- 2026-04-19$50KTAKEDA PHARMACEUTICALS AMERICA INC.Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, mental health, opioid abuse, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, plasma therapy, step therapy, and PBM reform; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order. General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation. Issues related to tax reform; R&D tax credit; orphan drug tax credit; Section 899; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation. Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues. Issues related to pharmaceutical IP, supply chai
- 2026-04-18$50KTAKEDA PHARMACEUTICALS AMERICA INC.Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act. Issues related to Plasma-Derived Therapies; Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to National Priority Voucher (CNPV) program.
- 2026-04-10$50KTAKEDA PHARMACEUTICALS AMERICA INC.International tax reform.
- 2026-04-09$30KTIBER CREEK GROUP ON BEHALF OF TAKEDA PHARMACEUTICALS AMERICA INC.Issues related to drug pricing.
Loading trade analytics…
All Disclosed Trades
Page 1 · 3 of 3 shown| Date | Member | Action | Amount | Observed Gap | Receipt |
|---|---|---|---|---|---|
| 2023-08-29 | RVirginia Foxx | SELL | $15K – $50K | 4d | receipt → |
| 2023-08-29 | RVirginia Foxx | BUY | $15K – $50K | 4d | receipt → |
| 2023-02-16 | RVirginia Foxx | BUY | $1K – $15K | 13d | receipt → |
“Observed gap” is the calendar distance from transaction date to filing date; only gaps over 45 days receive an apparent-delay marker.